Abstract: The present disclosure provides for methods of treating or preventing a headache disorder in a subject including administering to the subject a CCL2-CCR2 signaling inhibiting agent.

Abstract: Compositions, methods, and systems for labeling cells to track cell lineage within single-cell transcriptomic, genomic, epigenomic, and/or multi-omics assays are disclosed.

Abstract: Systems and methods for locating tagged objects in remote regions are presented herein, in one embodiment, a method of locating tagged objects in remote regions includes creating a signal strength probability density map by. The method also includes transmitting first packets of data from at least one first tag to a plurality of stations and determining, by a plurality of stations, received signal strength indicator (RSSI) for received first packets of data. The method also includes transmitting, by the plurality of stations, the RSSI to an uplink node; and transmitting, by the uplink node, the RSSI to a database. The method further includes determining, by the database, the signal strength probability density map representative of probabilistic locations of the at least one first tag; and transmitting second packets of data from a second tag to the plurality of stations.

Abstract: Compositions and methods useful for vaccinating for or preventing a Coronavinus infection, antibody screening, and variant prediction are provided. The present disclosure also provides for compositions and methods useful for sera diagnostics, treatment screening, and methods of making the compositions described herein.

Abstract: Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and/or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.

Abstract: The present invention is directed to various methods of suppressing inflammasome activation. For example, the present invention relates to various methods of treating a disease or condition in which inflammation contributes to the disease or condition state.

Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.

Abstract: Among the various aspects of the present disclosure is the provision of conjugate systems and methods of use thereof. In an aspect, the conjugate system includes an adenovirus comprising an exterior surface, and at least one polypeptide comprising a first domain and a second domain, and wherein the exterior surface comprises a peptide tag capable of binding to a binding partner.

Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.

Abstract: Systems and methods for monitoring and controlling delivery of a therapeutic compound to a brain of a subject using FUS-BBBD are disclosed. The method includes treating the brain of the subject with focused ultrasound in combination with microbubbles for blood-brain barrier disruption (FUS-BBBD), administering the therapeutic agent to the subject; and obtaining a map of a concentration of the therapeutic agent delivered to the brain of the subject using passive cavitation imaging (PCI). The delivery of focused sound may be modulated to match the map of the concentration of the therapeutic agent delivered to the brain of the subject to a desired spatial distribution of the therapeutic agent.

Abstract: The present invention is a method or system for acceptance testing and commissioning of a LINAC and treatment planning system (TPS). For a LINAC commissioning, the present invention collects reference data from a fully calibrated LINAC and compares the reference data with machine performance data collected from LINAC. The compared results are analyzed to assess accuracy of the testing LINAC. For a TPS commissioning, the present invention collects standard reference data from standard treatment plans and standard input data and compares the standard reference data with results from standard tests that are performed by a testing treatment plan system. The compares results are analyzed to assess accuracy of the testing treatment plan system.

Abstract: Among the various aspects of the present disclosure is the provision of systems and methods for producing systems and methods for the computational design of CRISPR guide RNAs for strain-specific control of microbiota consortia.

Abstract: Systems and methods for the selection of a treatment for pancreatic adenocarcinoma (PDAC) in a patient in need based on single-cell RNA sequencing data obtained from a tumor biopsy sample obtained prior to treatment are disclosed. Also disclosed are systems and methods for predicting a clinical outcome of a pancreatic adenocarcinoma (PDAC) patient based on the single-cell RNA sequencing data.

Abstract: The present disclosure provides for compositions of, synthetic methods of, and methods for use of dihydrofolate synthase (DHFS) inhibiting agents.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods to detect immune system activation and inhibition, including but not limited to a pro-tumor radioresistant tumor microenvironment, including but not limited to overexpressed SERPINB3, and the modulation of this microenvironment with modulators, including but not limited to STAT inhibitors, which can improve radiotherapy in cancer patients.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.

Abstract: Solutions having a solvent and a cold atmospheric plasma dissolved in the solvent are described. Methods and systems of forming cold atmospheric plasma (CAP)-containing solutions are also described. A system for producing (CAP)-containing solutions includes a gas source; a plasma generating device having a hollow body fluidically coupled with the gas source, a closed proximal end and an open distal end, the hollow body receiving gas from the gas source, and at least one electrode in or about the hollow body and ionizing the gas to discharge a cold atmospheric plasma (CAP) from the open distal end; and a container for housing a fluid, the open distal end of the plasma generating device in fluid communication with an inner portion of the container. CAP-containing solutions can be used in treatment of cancer cells, infected tissue sterilization, microorganism inactivation, promotion of wound healing, skin regeneration, and blood coagulation, and teeth bleaching/whitening.

Abstract: Systems and methods for virtual reality or augmented reality (VR/AR) visualization of 3D medical images using a VR/AR visualization system are disclosed that includes a computing device operatively coupled to a VR/AR device, which includes a holographic display and at least one sensor. The holographic display is configured to display a holographic image to an operator. The computing device is configured to receive at least one stored 3D image of a subject's anatomy and at least one real-time 3D position of at least one surgical instrument, to register the at least one real-time 3D position of the at least one surgical instrument to correspond to the at least one 3D image of the subject's anatomy, and to generate the holographic image comprising the at least one real-time position of the at least one surgical instrument overlaid on the at least one 3D image of the subject's anatomy.

Abstract: In one aspect, a composition for sustained release of oxygen to a tissue is disclosed that includes at least one core-shell oxygen release microsphere (ORM), wherein the core includes a water-soluble polymer-reactive oxygen species (ROS) complex and the shell includes a biodegradable polymer conjugated to a ROS-scavenging enzyme. In some aspects, the reactive oxygen species includes hydrogen peroxide (H2O2), the ROS-scavenging enzyme includes catalase, the water-soluble polymer includes polyvinylpyrrolidone (PVP), and the biodegradable polymer includes poly(N-isopropylacrylamide-co-2-hydroxyethyl methacrylate-co-acrylate-oligolactide-co-Nacryloxysuccinimide)[poly(NIPAAm-co-HEMA-co-AOLA-co-NAS)].